EGFR and neoplasm: In a recent study, HNSCC tumours collected from patients with MAPK1p.E322K mutation and treated with EGFR inhibitor, conferred heightened sensitivity to erlotinib in vivo and proceeding to patient recruitment in a clinical trial [43].